A recent study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published in the 2 October 2009 issue of the Journal “Science” (The number 2 journal in General science with an I.F of 31.477 )by Prof Dominic J. Withers, Dr. Selman C and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Life-span extension therapy: AMPKα2/PRKAA2 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Life-span extension therapy: AMPKα2/PRKAA2 (5′-AMP-activated protein kinase catalytic subunit alpha-2) inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene, 14/June/2015, 9.48 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Significance: This study suggests that AMPKα2/PRKAA2 (5′-AMP-activated protein kinase catalytic subunit alpha-2), by increasing the expression of its target gene, it may decrease the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase). Thereby, it may promote resistance to bone, immune, and motor dysfunction. Thus, pharmacological formulations encompassing “AMPKα2/PRKAA2 activators“ may be used to extend the life span of an individual.
Undisclosed information: How AMPKα2/PRKAA2 decreases the expression of p70S6 Kinase